Press Releases

Date	Title
2/11/21	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
2/1/21	Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics
1/27/21	Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
1/26/21	Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
1/12/21	Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
1/12/21	Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
1/6/21	Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform
1/5/21	Vir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference

Vir - Investor Relations Menu